Molecular monitoring of chronic myeloid leukemia: International standardization of BCR-ABL1 quantitation

Journal of Molecular Diagnostics

Volumn 15, Issue 5, 2013, Pages 556-564

  Zhen, Chaojie ^a   Wang, Y Lynn ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; GENE CONTROL; HUMAN; LONG TERM SURVIVAL; MOLECULARLY TARGETED THERAPY; PATIENT MONITORING; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STANDARDIZATION; TREATMENT RESPONSE;

FUSION PROTEINS, BCR-ABL; GENETIC TESTING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; REFERENCE STANDARDS;

EID: 84882289747     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.05.010     Document Type: Review

References (56)

1. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. Zimmermann, and N.B. Lydon Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
2. S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J.J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J.L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J.M. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A.E. Bolton, R. Capdeville, and B.J. Druker Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
3. P.C. Nowell, and D.A. Hungerford Minute chromosome in human chronic granulocytic leukemia Science 132 1960 1497
4. J.D. Rowley Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 243 1973 290 293
5. B.J. Druker Translation of the Philadelphia chromosome into therapy for CML Blood 112 2008 4808 4817
6. B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, F. Cervantes, A. Hochhaus, B.L. Powell, J.L. Gabrilove, P. Rousselot, J. Reiffers, J.J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J.L. Nielsen, J.P. Radich, B. Simonsson, K. Taylor, M. Baccarani, C. So, L. Letvak, and R.A. Larson Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
7. T.P. Hughes, A. Hochhaus, S. Branford, M.C. Muller, J.S. Kaeda, L. Foroni, B.J. Druker, F. Guilhot, R.A. Larson, S.G. O'Brien, M.S. Rudoltz, M. Mone, E. Wehrle, V. Modur, J.M. Goldman, and J.P. Radich Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Blood 116 2010 3758 3765
8. S. Branford Chronic myeloid leukemia: molecular monitoring in clinical practice Hematology Am Soc Hematol Educ Program 2007 376 383
9. S. Branford, T.P. Hughes, and Z. Rudzki Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics Br J Haematol 107 1999 587 599
10. H.M. Kantarjian, M. Talpaz, J. Cortes, S. O'Brien, S. Faderl, D. Thomas, F. Giles, M.B. Rios, J. Shan, and R. Arlinghaus Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia Clin Cancer Res 9 2003 160 166
11. M. Emig, S. Saussele, H. Wittor, A. Weisser, A. Reiter, A. Willer, U. Berger, R. Hehlmann, N.C. Cross, and A. Hochhaus Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR Leukemia 13 1999 1825 1832
12. H. Kantarjian, C. Schiffer, D. Jones, and J. Cortes Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods Blood 111 2008 1774 1780
13. K.A. Kreuzer, U. Lass, A. Bohn, O. Landt, and C.A. Schmidt LightCycler technology for the quantitation of bcr/abl fusion transcripts Cancer Res 59 1999 3171 3174
14. Y.L. Wang, A. Bagg, W. Pear, P.C. Nowell, and J.L. Hess Chronic myelogenous leukemia: laboratory diagnosis and monitoring Genes Chromosomes Cancer 32 2001 97 111
15. F.J. Giles Molecular monitoring of BCR-ABL transcripts: standardization needed to properly use, and further investigate the value of, a critical surrogate marker for success in therapy of chronic myeloid leukemia US Oncol Hematol 7 2011 138 142
16. M. Baccarani, F. Castagnetti, G. Gugliotta, F. Palandri, and S. Soverini Response definitions and European Leukemianet Management recommendations Best Pract Res Clin Haematol 22 2009 331 341
17. H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner, M. Talpaz, B. Druker, J. Goldman, S.G. O'Brien, N. Russell, T. Fischer, O. Ottmann, P. Cony-Makhoul, T. Facon, R. Stone, C. Miller, M. Tallman, R. Brown, M. Schuster, T. Loughran, A. Gratwohl, F. Mandelli, G. Saglio, M. Lazzarino, D. Russo, M. Baccarani, and E. Morra Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
18. E. Jabbour, H. Kantarjian, S. O'Brien, J. Shan, A. Quintas-Cardama, S. Faderl, G. Garcia-Manero, F. Ravandi, M.B. Rios, and J. Cortes The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors Blood 118 2011 4541 4546 quiz 4759
19. T.P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M.L. Hensley, I. Gathmann, A.E. Bolton, I.C. van Hoomissen, J.M. Goldman, and J.P. Radich Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
20. J. Cortes, M. Talpaz, S. O'Brien, D. Jones, R. Luthra, J. Shan, F. Giles, S. Faderl, S. Verstovsek, G. Garcia-Manero, M.B. Rios, and H. Kantarjian Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate Clin Cancer Res 11 2005 3425 3432
21. G. Saglio, D.W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, C. Lobo, R. Pasquini, R.E. Clark, A. Hochhaus, T.P. Hughes, N. Gallagher, A. Hoenekopp, M. Dong, A. Haque, R.A. Larson, and H.M. Kantarjian Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
22. R.A. Larson, A. Hochhaus, T.P. Hughes, R.E. Clark, G. Etienne, D.W. Kim, I.W. Flinn, M. Kurokawa, B. Moiraghi, R. Yu, R.E. Blakesley, N.J. Gallagher, G. Saglio, and H.M. Kantarjian Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: eNESTnd 3-year follow-up Leukemia 26 2012 2197 2203
23. H. Kantarjian, N.P. Shah, A. Hochhaus, J. Cortes, S. Shah, M. Ayala, B. Moiraghi, Z. Shen, J. Mayer, R. Pasquini, H. Nakamae, F. Huguet, C. Boque, C. Chuah, E. Bleickardt, M.B. Bradley-Garelik, C. Zhu, T. Szatrowski, D. Shapiro, and M. Baccarani Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
24. H.M. Kantarjian, N.P. Shah, J.E. Cortes, M. Baccarani, M.B. Agarwal, M.S. Undurraga, J. Wang, J.J. Ipina, D.W. Kim, M. Ogura, C. Pavlovsky, C. Junghanss, J.H. Milone, F.E. Nicolini, T. Robak, J. Van Droogenbroeck, E. Vellenga, M.B. Bradley-Garelik, C. Zhu, and A. Hochhaus Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood 119 2012 1123 1129
25. F.X. Mahon, D. Rea, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Etienne, J. Reiffers, and P. Rousselot Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 2010 1029 1035
26. P. Rousselot, F. Huguet, D. Rea, L. Legros, J.M. Cayuela, O. Maarek, O. Blanchet, G. Marit, E. Gluckman, J. Reiffers, M. Gardembas, and F.X. Mahon Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood 109 2007 58 60
27. N.C. Cross, H.E. White, M.C. Muller, G. Saglio, and A. Hochhaus Standardized definitions of molecular response in chronic myeloid leukemia Leukemia 26 2012 2172 2175
28. T.P. Hughes, and S. Branford Monitoring disease response to tyrosine kinase inhibitor therapy in CML Hematology Am Soc Hematol Educ Program 2009 477 487
29. A. Hochhaus, S.G. O'Brien, F. Guilhot, B.J. Druker, S. Branford, L. Foroni, J.M. Goldman, M.C. Muller, J.P. Radich, M. Rudoltz, M. Mone, I. Gathmann, T.P. Hughes, and R.A. Larson Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
30. D.M. Ross, S. Branford, S. Moore, and T.P. Hughes Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL Leukemia 20 2006 664 670
31. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, and C.L. Sawyers Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
32. N.P. Shah, J.M. Nicoll, B. Nagar, M.E. Gorre, R.L. Paquette, J. Kuriyan, and C.L. Sawyers Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
33. N.P. Shah, and C.L. Sawyers Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias Oncogene 22 2003 7389 7395
34. J.F. Apperley Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 2007 1018 1029
35. D. Jones, S. Kamel-Reid, D. Bahler, H. Dong, K. Elenitoba-Johnson, R. Press, N. Quigley, P. Rothberg, D. Sabath, D. Viswanatha, K. Weck, and J. Zehnder Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology J Mol Diagn 11 2009 4 11
36. J.F. Apperley Part II: management of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 2007 1116 1128
37. S. Branford, Z. Rudzki, S. Walsh, I. Parkinson, A. Grigg, J. Szer, K. Taylor, R. Herrmann, J.F. Seymour, C. Arthur, D. Joske, K. Lynch, and T. Hughes Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood 102 2003 276 283
38. J.P. Radich The biology of CML blast crisis Hematology Am Soc Hematol Educ Program 2007 384 391
39. A. Aguayo, and S. Couban State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment Leuk Lymphoma 50 Suppl 2 2009 1 8
40. J.E. Cortes, H. Kantarjian, N.P. Shah, D. Bixby, M.J. Mauro, I. Flinn, T. O'Hare, S. Hu, N.I. Narasimhan, V.M. Rivera, T. Clackson, C.D. Turner, F.G. Haluska, B.J. Druker, M.W. Deininger, and M. Talpaz Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2012 2075 2088
41. D. Marin, D. Milojkovic, E. Olavarria, J.S. Khorashad, H. de Lavallade, A.G. Reid, L. Foroni, K. Rezvani, M. Bua, F. Dazzi, J. Pavlu, M. Klammer, J.S. Kaeda, J.M. Goldman, and J.F. Apperley European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 112 2008 4437 4444
42. M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, A. Gratwohl, F. Guilhot, M. Horowitz, T. Hughes, H. Kantarjian, R. Larson, D. Niederwieser, R. Silver, and R. Hehlmann Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 2006 1809 1820
43. L.P. Akard, and Y.L. Wang Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners Clin Lymphoma Myeloma Leuk 11 2011 385 395
44. T. Zhang, S. Grenier, B. Nwachukwu, C. Wei, J.H. Lipton, and S. Kamel-Reid Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations J Mol Diagn 9 2007 421 430
45. College of American Pathologists (CAP). Minimal Residual Disease (MRD-A) Survey 2012. 2012, Northfield, IL
46. T. Hughes, M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, M. Baccarani, J. Cortes, N.C. Cross, B.J. Druker, J. Gabert, D. Grimwade, R. Hehlmann, S. Kamel-Reid, J.H. Lipton, J. Longtine, G. Martinelli, G. Saglio, S. Soverini, W. Stock, and J.M. Goldman Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 2006 28 37
47. S. Branford, N.C. Cross, A. Hochhaus, J. Radich, G. Saglio, J. Kaeda, J. Goldman, and T. Hughes Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia Leukemia 20 2006 1925 1930
48. S. Branford, L. Fletcher, N.C. Cross, M.C. Muller, A. Hochhaus, D.W. Kim, J.P. Radich, G. Saglio, F. Pane, S. Kamel-Reid, Y.L. Wang, R.D. Press, K. Lynch, Z. Rudzki, J.M. Goldman, and T. Hughes Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials Blood 112 2008 3330 3338
49. E. Beillard, N. Pallisgaard, V.H. van der Velden, W. Bi, R. Dee, E. van der Schoot, E. Delabesse, E. Macintyre, E. Gottardi, G. Saglio, F. Watzinger, T. Lion, J.J. van Dongen, P. Hokland, and J. Gabert Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program Leukemia 17 2003 2474 2486
50. Y.L. Wang, J.W. Lee, E. Cesarman, D.K. Jin, and B. Csernus Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts J Mol Diagn 8 2006 231 239
51. J.W. Lee, Q. Chen, D.M. Knowles, E. Cesarman, and Y.L. Wang beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia J Mol Diagn 8 2006 385 389
52. H.E. White, P. Matejtschuk, P. Rigsby, J. Gabert, F. Lin, Y. Lynn Wang, S. Branford, M.C. Muller, N. Beaufils, E. Beillard, D. Colomer, D. Dvorakova, H. Ehrencrona, H.G. Goh, H. El Housni, D. Jones, V. Kairisto, S. Kamel-Reid, D.W. Kim, S. Langabeer, E.S. Ma, R.D. Press, G. Romeo, L. Wang, K. Zoi, T. Hughes, G. Saglio, A. Hochhaus, J.M. Goldman, P. Metcalfe, and N.C. Cross Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA Blood 116 2010 e111 e117
53. N.C. Cross Standardisation of molecular monitoring for chronic myeloid leukaemia Best Pract Res Clin Haematol 22 2009 355 365
54. M.C. Muller, N.C. Cross, P. Erben, T. Schenk, B. Hanfstein, T. Ernst, R. Hehlmann, S. Branford, G. Saglio, and A. Hochhaus Harmonization of molecular monitoring of CML therapy in Europe Leukemia 23 2009 1957 1963
55. J. Saldanha, M. Silvy, N. Beaufils, R. Arlinghaus, G. Barbany, S. Branford, J.M. Cayuela, G. Cazzaniga, M. Gonzalez, D. Grimwade, V. Kairisto, K. Miyamura, M. Lawler, T. Lion, E. Macintyre, F.X. Mahon, M.C. Muller, M. Ostergaard, H. Pfeifer, G. Saglio, C. Sawyers, O. Spinelli, V.H. van der Velden, J.Q. Wang, K. Zoi, V. Patel, P. Phillips, P. Matejtschuk, and J. Gabert Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements Leukemia 21 2007 1481 1487
56. J. Moravcova, J. Rulcova, K.M. Polakova, and H. Klamova Control genes in international standardization of real-time RT-PCR for BCR-ABL Leukemia Res 33 2009 582 584